Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
M.D. Anderson Cancer Center
With
National Cancer Institute (NCI)
PRIMARY OBJECTIVE:
I. To provide evidence that the clipped lymph node and Magseed can be successfully retrieved in the excised surgical specimen when Magseed and Sentimag are used for targeted axillary dissection in breast cancer patients.
OUTLINE:
Patients receive the Magseed marker via ultrasound guided injection into the previously clipped lymph node or within perinodal tissue =\< 3 mm from the clipped node. Patients then undergo axillary lymph node localization and targeted dissection within 30 days.
After completion of study, patients are followed up within 6-22 days post-surgery.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed cT0-4, N1 breast cancer
Axillary lymph node metastasis with pathologic confirmation by needle biopsy
Clip placed in the sampled axillary lymph node before completing chemotherapy
Received neoadjuvant chemotherapy prior to surgical resection
Scheduled for targeted axillary dissection (defined as selective localization and removal of the clipped node and sentinel lymph node dissection \[SLND\])
Eastern Cooperative Oncology Group (ECOG) performance status 0-2
You may not be if
Distant metastases
Inflammatory breast cancer
Prior surgical axillary procedure including SLND or axillary node excision
Prior history of breast cancer in the ipsilateral breast
History of lymphoma
The subject is known to be pregnant. Premenopausal patients under the age of 50 must have a pregnancy test performed as standard of care before the MagSeed is placed
Previous radiation to the breast or axilla
Pacemaker of other implantable device in the chest wall
